Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data

TheFly reported connected June 17 that RBC Capital accrued its terms people for EWTX to $59 from $48 portion maintaining an Outperform standing connected the shares. The steadfast highlighted the company's 12-week results from the '7500 HCM trial, noting that the information demonstrated encouraging information and efficacy outcomes. RBC Capital believes the findings could enactment a aboriginal Phase 3 proceedings plan without the request for titration echocardiograms, perchance improving the therapy's usability successful real-world settings. The steadfast besides emphasized EWTX's broader cardiology opportunity, citing the imaginable of '7500 and the company's pipeline to enactment important semipermanent growth.

Earlier this month, connected June 1, Edgewise Therapeutics, Inc. (NASDAQ:EWTX) announced a definitive statement with Servier for the acquisition of sevasemten and its muscular dystrophy concern for $1.55 cardinal successful upfront currency and up to $1.1 cardinal successful further milestone payments, representing imaginable full information of $2.65 billion. The transaction strengthens EWTX's fiscal presumption and allows the institution to absorption its strategy connected advancing its cardiovascular pipeline. Following the deal, Edgewise volition displacement into a cardiovascular-focused company, with programs including EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF, and EDG-003. The institution plans to proceed progressing its cardiovascular improvement programs utilizing the enhanced fiscal flexibility.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is simply a clinical-stage biopharmaceutical institution processing precision oral medicines for terrible musculus diseases, utilizing a unsocial attack focused connected protecting skeletal and cardiac muscles from damage.

While we admit the imaginable of EWTX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.